occasionally subtle
Cosimo Galluzzi
Peter Solarz

Origami Around
let's talk about Bridgerton tea, my ask is open
No title available

JVL

izzy's playlists!
Misplaced Lens Cap
🪼
Mike Driver
Aqua Utopia|海の底で記憶を紡ぐ
Not today Justin
taylor price

Discoholic 🪩

@theartofmadeline
styofa doing anything

blake kathryn

No title available
Alisa U Zemlji Chuda
seen from Belarus
seen from Italy
seen from Spain
seen from United States

seen from Malaysia
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States

seen from Türkiye

seen from United States

seen from South Korea
seen from United Arab Emirates

seen from Mexico

seen from United States
seen from Mexico
seen from United States
@stonedscience
UX Crash Course: Stupid Question 23 of 30
UX designers hate designing forms as much — or more — than users hate using them. But when developers tell you that your super-simple form won’t work, you might feel stuck. So let’s answer:
“Why can’t credit card numbers include spaces?”
Credit card forms are one of my favourite examples of usability because they are super simple and super complicated at the same time.
The fundamental requirements for a credit card form are pretty simple. The card number, the expiry date, the security code, and a smile.
Everything else is details. But in this case, those details might be the difference between buying an authentic Harry Potter wand made of real wood from Hogwarts, or going to Comicon in muggle clothes like an idiot.
i.e. — completing the purchase or not.
The real number that is printed on the plastic credit card includes spaces, so why can’t the user include those spaces when they type it in?
****
The stupid/lazy answer:
“Our database isn’t set up to handle the spaces.”
****
The real answer:
A credit card number can ABSOLUTELY include spaces.
There is no technical reason why your form cannot be built to accept spaces in the credit card number. That’s just not the way that input field works by default.
When you add intelligence like that to your forms it takes extra development time, but it will also help more people complete their purchase.
Your credit card form can be built to save the number without spaces.
It can be built to add spaces as the user types.
It can be built to automatically detect the type of credit card when you enter the first few numbers (Visa starts with 4, Mastercard with 5, AmEx with 3, etc.)
It can be built to display the information directly in a digital version of the card, so you can compare them side-by-side!
All of these “upgrades” just take time. You need to consider the time versus the benefit. As all good developers say: “anything is possible, but everything isn’t realistic.”
****
Why this isn’t a stupid question: Sometimes UX and code work against each other.
When you design a simpler exerience, sometimes that creates a more complex project for the person coding it.
In the same way that designers are often motivated to simplify their own lives by hiding things in the UI, developers are often motivated to simplfiy their own lives by saying it “can’t be done” instead of “I would prefer not to do that, because it annoys the fuck out of me.”
When you are told that your design can’t be done, just ask why. It is quite ok to ask “which part of this design is impossible to build?”
The answer usually starts with “well, it’s not impossible to build, but…”
Then you can have a smart discussion about the trade-offs.
It is probably worth it to allow spaces and remove any stupid typos a user might make. It prevents mistakes.
It might not be worth it to allow users to add a picture of their own face to the digital version of the card, using their webcam.
****
Remember: developers and UX designers can help each other, and neither of you should lie to get what you want. It’s not about you. It’s about the user.
****
Tomorrow we will answer: “How do you make a design responsive?”
Some cool canvas pixel manipulation
Awesome new writing app
(via Victoria Hoey (@spun_bunny) • Instagram photos and videos)
(via ▶ Instant Ice - Waterbending In Real Life! - YouTube)
(via ▶ Instant Ice - Waterbending In Real Life! - YouTube) tune in later and I’ll teach you how to build a Freeze “Ray” (aka squirt-gun)
Think it's impossible to walk on liquid? Think again. Join Anthony and Tara as they make a pool of non-Newtonian fluid, out of oobleck, and walk, run, jump and bike across it. Thanks, science, for the awesome cornstarch pool party!
Non-Newtonian Liquids become solid when you apply pressure.
What is the MOST distressing aspect of this picture.
a.) Both these books are listed as NON FICTION?
b.) “The Zombie Survival Guide” is also a REFERENCE BOOK?
c.) There are 3 people waiting for a copy of “The Bible” on audio-download?
The Grid
The REVOLUTION will be optimized. It will be shared, stared, stumbled, tumbled, pinned, tweeted, liked, and dug. It will broadcast the news, increase views on You Tube. Create an electronic audience analogous of the way WE peruse. So what’cha gonna to do? On which side of the digital divide, will your pixelated information reside? Swipe right to say, "hi" to the new HTML5... Wait, Java? Really bro I wrote this whole thing and you're using Java?
The Grid I must admit, you’ve peaked my interest. No nonsense responsive, designs for the graphically itinerant. How did you solve for the problems of content logarithms? Java’s idea of CSS is Can’t Style Shit.
Nerd Poem #1
Go ahead, You can call me, “Old Flash-nd,” or “Outta date” and just keep on laughing. But, I put the math in.
Listen here, my dear. To animate, a bouncing ball needs to fall at a parabolic frame rate. (calculate) Try to equate, my sense of time, with your little screen-grab tactics? I come up from behind... (and) give you a SWF kick in the assets.
Desperately Seeking Stoners
Stoned Science is looking for guests who would like to participate in episodes airing in July.
If you live in the LA area and would like to know more about the show
Email: [email protected]
Study provides comprehensive look at brain cancer treatments
Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press journal Neuro-Oncology.
The study, Towards Precision Medicine in Glioblastoma: The Promise and The Challenges, covers how these highly invasive and almost-always-deadly brain cancers may be treated, reviews the continuing challenges faced by researchers and clinicians, and presents the hope for better treatments by harnessing the power of the human genome.
The study also describes a pioneering clinical trial underway for 15 patients at UCSF, guided by TGen research, in which an individual patient’s genomic profile is used to offer treatment recommendations to an expert, multidisciplinary panel.
“This study thoroughly explores how we arrived at the current standard-of-care, and how – through cutting-edge genomic technologies – we might find better answers for these patients who need our help today,” said Dr. Jeffrey Trent, TGen President and Research Director and the study’s senior author.
Funded by The Ben & Catherine Ivy Foundation, the study is one of several simultaneous and coordinated efforts seeking to uncover the molecular source of this deadly brain cancer with the goal of prolonging survival of glioblastoma patients.
“Despite pivotal advances in the characterization of genomic mutation in glioblastoma, targeted drug agents have so far shown minimal effect in clinical trials, and patient survival remains poor,” said Dr. Michael D. Prados, the Charles B. Wilson, MD, Endowed Chair in Neurological Surgery at UCSF, and one of the study’s co-lead authors.
One of the major difficulties in treating brain tumors is finding drugs that can penetrate the blood-brain barrier, which buffers the brain from the rest of the body’s blood-circulatory system. Located along capillaries, the blood-brain barrier protects the brain from rapid changes in the body’s metabolic conditions and minimizes exposure to molecules that are toxic to neurons in the brain.
“This study outlines strategies for overcoming past failures, primarily by applying targeted combination therapies that match the tumors’ genetic changes with drug compounds that can reach the central nervous system,” said Dr. Sara Byron, Research Assistant Professor in TGen’s Center for Translational Innovation, and the study’s other co-lead author.
Another major challenge in treating glioblastoma is its intrusive penetration into adjoining tissues, which prevents the complete surgical removal of the tumors from the brain, even with follow-up radiation and chemotherapy: “It is this invasive, infiltrative disease component that is the ultimate cause of recurrence, resistance and death,” the study says.
“All patients will continue to show tumor growth and progression because of rapidly proliferating infiltrative disease remaining after surgery,” according to the study. “Effective treatment for glioblastoma remains an unmet need.”
The only FDA-approved drugs to treat glioblastoma are temozolomide, nitrosoureas, and bevacizumab.
In the clinical trial begun at UCSF, multiple biopsies are performed on each patient at the time of surgery in different regions of the brain tumor. That is followed by extensive genome-wide profiling, leading to a selection of drugs that would target the brain cancer and diffuse regions of the lesion that cannot be removed by surgery.
Drug selection is individualized, and multiple FDA-approved agents (up to four) allowed. “Rules” for drug selection are implemented, using the specialized drug pharmacopeia designed for this trial. The drugs are chosen carefully, considered with knowledge about the ability of the drug to reach the brain and the patient’s past treatment history and concomitant therapies, with the assistance of multi-specialty, multi-institutional molecular tumor board that drafts a report to the treating physician.
In addition, “Small, informative, tissue-based clinical trials that take into account the individual molecular features of patients and provide early ‘go’ or 'no go’ decisions are needed and should be prioritized over unselected, large, population-based strategies,” the study recommends.
A separate clinical trial that follows this path, also guided by TGen genomic research, is underway at Barrow Neurological Institute. This clinical trial also is funded by The Ben & Catherine Ivy Foundation. For more about this clinical trial, go to: http://www.tgen.org/home/news and click on March 10, 2015.
“These studies, and their associated clinical trials, have the potential to lift our knowledge of glioblastoma to an unprecedented new level,” said Catherine Ivy, President of The Ben & Catherine Ivy Foundation. “Developing drug compounds that breach the blood-brain barrier and are effective against tumors would fulfill one of the medical community’s most critical unmet needs, and boost the hopes of brain tumor patients everywhere.”
What does this look like to you?
See if you can guess what this icon is?
Just a little hello from the head Bunny of the soon to be Stoned Science podcast. Ears up, Eyes open, It’s Saturday night… start smoke’n.